Skip to main content

Advertisement

Log in

Investigation of the impact of hepatic impairment on the pharmacokinetics of dacomitinib

  • PHASE I STUDIES
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Dacomitinib (PF-00299804) is a small-molecule inhibitor of the tyrosine kinases human epidermal growth factor receptor-1 (HER1; epidermal growth factor receptor, EGFR), HER2, and HER4 currently being developed for the treatment of lung cancer with sensitizing mutations in EGFR or refractory to EGFR-directed treatment. Dacomitinib is largely metabolized by the liver through oxidative and conjugative metabolism; therefore, determination of the impact of varying degrees of hepatic impairment on the pharmacokinetics (PK) of dacomitinib was warranted to ensure patient safety. In this phase I, open-label, parallel-group study, a single dose of dacomitinib was administered to healthy volunteers and to subjects with mild or moderate liver dysfunction, as determined by Child-Pugh classification. The primary goal of this study was to evaluate the effects of mild and moderate hepatic impairment on the single-dose PK profile of dacomitinib, as well as to assess the safety and tolerability in these subjects. Plasma protein binding and impact of hepatic function on the PK of the active metabolite PF-05199265 was also investigated. Twenty-five male subjects received dacomitinib 30 mg, with 8 subjects in the healthy- and mild-impairment cohorts and 9 subjects in the moderate-impairment cohort. Compared with healthy volunteers, there was no significant change in dacomitinib exposure in subjects with mild or moderate liver dysfunction and no observed alteration in plasma protein binding. No serious treatment-related adverse events were reported in any group, and dacomitinib was well tolerated. A dose adjustment does not appear necessary when administering dacomitinib to patients with mild or moderate hepatic impairment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Salomon DS, Brandt R, Ciardiello F, Normanno N (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183–232

    Article  CAS  PubMed  Google Scholar 

  2. Woodburn JR (1999) The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 82:241–250

    Article  CAS  PubMed  Google Scholar 

  3. Britten CD (2004) Targeting ErbB receptor signaling: a pan-ErbB approach to cancer. Mol Cancer Ther 3:1335–1342

    CAS  PubMed  Google Scholar 

  4. Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T, Zhao F, Vincent PW, Naumov GN, Bradner JE, Althaus IW, Gandhi L, Shapiro GI, Nelson JM, Heymach JV, Meyerson M, Wong KK, Janne PA (2007) PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 67:11924–11932

    Article  CAS  PubMed  Google Scholar 

  5. Ramalingam SS, Blackhall F, Krzakowski M, Barrios CH, Park K, Bover I, Seog Heo D, Rosell R, Talbot DC, Frank R, Letrent SP, Ruiz-Garcia A, Taylor I, Liang JQ, Campbell AK, O’Connell J, Boyer M (2012) Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 30:3337–3344

    Article  CAS  PubMed  Google Scholar 

  6. Abdul Razak AR, Soulières D, Laurie SA, Hotte SJ, Singh S, Winquist E, Chia S, Le Tourneau C, Nguyen-Tan PF, Chen EX, Chan KK, Wang T, Giri N, Mormont C, Quinn S, Siu LL (2013) A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck. Ann Oncol 24:761–769

    Article  CAS  PubMed  Google Scholar 

  7. Takahashi T, Boku N, Murakami H, Naito T, Tsuya A, Nakamura Y, Ono A, Machida N, Yamazaki K, Watanabe J, Ruiz-Garcia A, Imai K, Ohki E, Yamamoto N (2012) Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, −2, and −4 tyrosine kinases, in Japanese patients with advanced solid tumors. Invest New Drugs 30:2352–2363

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Jänne PA, Boss DS, Camidge DR, Britten CD, Engelman JA, Garon EB, Guo F, Wong S, Liang J, Letrent S, Millham R, Taylor I, Eckhardt SG, Schellens JH (2011) Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clin Cancer Res 17:1131–1139

    Article  PubMed Central  PubMed  Google Scholar 

  9. Masters JC, Mendes da Costa L, LaBadie R, Bello CL, Liang Y, Ni G, Ellery CG, Boutros T, Goldberg Z, Ruiz-Garcia A (2014) Effect of food and antacid treatment on the bioavailability of 45 mg tablet of dacomitinib relative to dacomitinib administration under fasted conditions. Clin Pharmacol Ther 95(S1):Abstract 395

    Google Scholar 

  10. Bello CL, Smith E, Ruiz-Garcia A, Ni G, Alvey C, Loi CM (2013) A phase I, open-label, mass balance study of [(14)C] dacomitinib (PF-00299804) in healthy male volunteers. Cancer Chemother Pharmacol 72:379–385

    Article  CAS  PubMed  Google Scholar 

  11. US Food and Drug Administration (2003) Guidance for industry: pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling. US Food and Drug Administration, Washington, DC

  12. Rodighiero V (1999) Effects of liver disease on pharmacokinetics. An update. Clin Pharmacokinet 37:399–431

    Article  CAS  PubMed  Google Scholar 

  13. Ruiz-Garcia A, Giri N, Labadie RR, Ni G, Boutros T, Richie N, Kocinsky HS, Checchio TM, Bello CL (2013) A phase I open-label study to investigate the potential drug–drug interaction between single-dose dacomitinib and steady-state paroxetine in healthy volunteers. J Clin Pharmacol 54:555–562

    Article  PubMed  Google Scholar 

  14. Horak J, White J, Harris AL, Verrill M, Carmichael J, Holt A, Cantarini M, Macpherson M, Swaisland A, Swaisland H, Twelves C (2011) The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib. Cancer Chemother Pharmacol 68:1485–1495

    Article  CAS  PubMed  Google Scholar 

  15. O’Bryant CL, Haluska P, Rosen L, Ramanathan RK, Venugopal B, Leong S, Boinpally R, Franke A, Witt K, Evans J, Belani C, Gail Eckhardt S, Ramalingam S (2012) An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function. Cancer Chemother Pharmacol 69:605–612

    Article  PubMed  Google Scholar 

  16. Schnell D, Buschke S, Fuchs H, Gansser D, Goeldner RG, Uttenreuther-Fischer M, Stopfer P, Wind S, Petersen-Sylla M, Halabi A, Koenen R (2014) Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment. Cancer Chemother Pharmacol 74(2):267-275. doi:10.1007/s00280-014-2484-y

  17. Verbeeck RK (2008) Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 64:1147–1161

    Article  CAS  PubMed  Google Scholar 

  18. Veilleneuve JP, Pichette V (2004) Cytochrome P450 and liver disease. Curr Drug Metab 5:273–282

    Article  Google Scholar 

  19. Adedoyin A, Arns PA, Richards WO, Wilkinson GR, Branch RA (1998) Selective effect of liver disease on the activities of specific metabolizing enzymes: investigation of cytochromes P450 2C19 and 2D6. Clin Pharmacol Ther 64:8–17

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Michael DeMicco (Anaheim Clinical Trials, LLC, Anaheim, CA, USA) for his contribution to the conduct of this study. We thank the study participants as well as the research personnel at the study sites. Medical writing support was provided by Rachel Mason from, and Rick Fleming for, ACUMED® (Tytherington, UK), an Ashfield Company, with funding from Pfizer Inc.

Ethical standards

This study was conducted in compliance with the ethical principles originating in or derived from the Declaration of Helsinki and in compliance with all International Conference on Harmonization (ICH) Good Clinical Practice (GCP) Guidelines. In addition, all local regulatory requirements were followed, in particular, those affording greater protection to the safety of trial participants. An institutional review board approved the protocol, and all participants gave written, informed consent. This trial was registered on ClinicalTrials.gov (NCT01571388).

Conflict of interest

This research was sponsored by Pfizer Inc. Nagdeep Giri, Joanna C Masters, Anna Plotka, Yali Liang, Tanya Boutros, Joseph O’Connell, and Carlo Bello are employees of Pfizer Inc. and own Pfizer stock. Patricia Pardo declares that she has no conflict of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Nagdeep Giri.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Giri, N., Masters, J.C., Plotka, A. et al. Investigation of the impact of hepatic impairment on the pharmacokinetics of dacomitinib. Invest New Drugs 33, 931–941 (2015). https://doi.org/10.1007/s10637-015-0256-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-015-0256-0

Keywords

Navigation